Logo

MYGN

Myriad Genetics, Inc.

MYGN

Myriad Genetics, Inc. • NASDAQ
$7.63 ▲ 0.39% (+0.03)
Market Cap $711.16 M
52w High $16.83
52w Low $3.76
Dividend Yield 0%
P/E -1.75
Volume 427.29K
Outstanding Shares 93.21M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $213.1M ▲ $481M ▲ $-330.5M ▼ -155.092% ▼ $-3.57 ▼ $-315M ▼
Q1-2025 $195.9M ▼ $163.2M ▼ $-100K ▲ -0.051% ▲ $-0.001 ▲ $-14.2M ▲
Q4-2024 $210.6M ▼ $189.9M ▲ $-42.5M ▼ -20.18% ▼ $-0.47 ▼ $-23.6M ▼
Q3-2024 $213.3M ▲ $169.8M ▼ $-22.1M ▲ -10.361% ▲ $-0.24 ▲ $-4.8M ▲
Q2-2024 $211.5M $183.6M $-36.7M -17.352% $-0.41 $-21.3M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $74.4M ▼ $677.3M ▼ $289.2M ▼ $388.1M ▼
Q1-2025 $91.8M ▼ $1.006B ▼ $301.2M ▼ $704.9M ▲
Q4-2024 $102.4M ▲ $1.028B ▼ $326.5M ▼ $701.1M ▼
Q3-2024 $99.9M ▲ $1.081B ▼ $349.6M ▲ $731.7M ▼
Q2-2024 $97.3M $1.085B $344.6M $740.5M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-330.5M ▼ $-13.6M ▲ $-6.9M ▲ $2.6M ▼ $-17.3M ▼ $-20.5M ▲
Q1-2025 $-100K ▲ $-16.3M ▼ $-8.3M ▼ $13.6M ▲ $-10.9M ▼ $-24.6M ▼
Q4-2024 $-42.5M ▼ $6.6M ▲ $-5.9M ▼ $2.1M ▲ $2.1M ▼ $700K ▲
Q3-2024 $-22.1M ▲ $700K ▼ $7.5M ▲ $-3.1M ▼ $8.6M ▲ $-5.6M ▲
Q2-2024 $-36.7M $2.6M $-6.4M $2.4M $-4.4M $-6.3M

Revenue by Products

Product Q3-2020Q1-2021Q2-2021Q3-2021
Diagnostics
Diagnostics
 $130.00M ▲$160.00M ▲$180.00M ▲$160.00M ▼
Other Segments
Other Segments
 $10.00M ▲$20.00M ▲$10.00M ▼$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Myriad has been growing its sales at a steady pace over the past five years, showing that demand for its genetic testing and related services is rising. At the same time, the company has not yet reached consistent profitability: operating income and net income have been negative each year. The losses, however, have generally been shrinking more recently, which signals improving cost control and scale. Overall, the business looks like it is moving along a path from heavy investment and restructuring toward a more sustainable earnings profile, but it is not there yet.

Balance Sheet

Balance Sheet The balance sheet shows a company that still has a solid equity base but has been gradually drawing it down through ongoing losses. Total assets have trended lower over time, reflecting divestments, write‑downs, or the use of cash to fund the business. Cash on hand has come down from earlier peaks, while debt has appeared and now represents a meaningful, though not dominant, part of the capital structure. In simple terms, Myriad still has financial resources, but its cushion is thinner than a few years ago, and management needs to balance growth initiatives with preserving balance sheet strength.

Cash Flow

Cash Flow Cash flow from the core business has been slightly negative in most recent years, which means the company is still consuming cash rather than generating it. Free cash flow has also been negative, although the most recent period shows a clear improvement compared with prior years. Capital spending has been modest, suggesting that cash use is coming more from operating losses than from heavy investment in physical assets. The trend toward less negative cash flow is encouraging, but the business remains dependent on its existing cash, credit, or future financing until operations consistently turn cash‑positive.

Competitive Edge

Competitive Edge Myriad holds a well‑recognized position in genetic testing, especially in hereditary cancer, prenatal screening, and pharmacogenomics. Its long history in the field, deep relationships with clinicians, and large proprietary genetic database give it a meaningful edge in test accuracy and clinical confidence. However, the broader genetic testing market has become crowded, with many rivals and ongoing pricing and reimbursement pressure. Myriad’s advantage rests on brand, data, and clinical validation rather than low cost, so maintaining physician trust and insurance coverage is critical to defending its share.

Innovation and R&D

Innovation and R&D Innovation is a central strength: Myriad has built proprietary technologies such as AMPLIFY for prenatal testing and RiskScore for more precise cancer risk assessment. The company is aggressively using artificial intelligence and machine learning to interpret genetic variants, streamline lab workflows, and enhance product performance. Its pipeline includes new prenatal screens, AI‑enhanced prostate cancer tests, molecular residual disease assays, and liquid biopsy companion diagnostics, all aimed at higher‑value, more personalized medicine. This depth of R&D and partnerships suggests a strong engine for future products, though the commercial success and reimbursement of these offerings remain key uncertainties.

Summary

Overall, Myriad looks like a science‑driven company transitioning from a long investment phase toward a more disciplined, growth‑with‑efficiency model. Revenue is rising and losses are narrowing, but the business is still not profitable and continues to use cash, which has gradually eroded its balance sheet cushion. Its competitive strengths lie in brand, data, clinician relationships, and advanced technology, offset by a dynamic, highly competitive market and reimbursement risks. The future story hinges on executing its innovation pipeline, converting scientific advantages into profitable, reimbursed tests, and stabilizing cash generation while maintaining enough financial flexibility to keep investing in growth.

NEWS

November 25, 2025 · 4:15 PM UTC

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Read more

November 11, 2025 · 9:00 AM UTC

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Read more

November 3, 2025 · 4:05 PM UTC

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

Read more

October 31, 2025 · 9:05 AM UTC

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

Read more

October 27, 2025 · 4:15 PM UTC

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Read more